The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

The phase 1b PRECISE-AD trial is currently investigating PMN310 in patients with mild cognitive impairment due to AD and in those with mild AD.

ProMIS Neurosciences shares surged after the company said the Food and Drug Administration granted a fast-track designation to the company's in-development treatment for Alzheimer's disease. Shares ...

Scientists at UCSF and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in ...

A study comparing the gene expression signature of Alzheimer's disease with those elicited by 1,300 approved drugs found a combination of two cancer medications that could treat the most common form ...

ProMIS Neurosciences (NASDAQ:PMN), a clinical-stage biotech stock focused on neurodegenerative diseases, has been granted the ...

Scientists at UC San Francisco and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that ...

TWO NHS drugs could be combined to treat, and even reverse, the most common form of dementia, scientists claim. A pair of ...

Investing.com -- ProMIS Neurosciences Inc (NASDAQ: PMN) stock surged 145% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead ...

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease ...